HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: db06-1226v1 56/7/1825    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugimoto, H. Articles by Kalluri, R. Search for Related Content PubMed PubMed Citation Articles by Sugimoto, H. Articles by Kalluri, R. Social Bookmarking                What's this?

Renal Fibrosis and Glomerulosclerosis in a New Mouse Model of Diabetic Nephropathy and Its Regression by Bone Morphogenic Protein-7 and Advanced Glycation End Product Inhibitors

¹ Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
² Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts
³ Harvard–Massachusetts Institute of Technology Division of Health Sciences and Technology, Boston, Massachusetts

Address correspondence and reprint requests to Raghu Kalluri, Associate Professor of Medicine, Harvard Medical School, Chief, Division of Matrix Biology, Department of Medicine, RW 514, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215. E-mail: rkalluri{at}bidmc.harvard.edu

Abbreviations: AGE, advanced glycation end product; BMP, bone morphogenic protein; CML, carboxymethyllysine; ESRD, end-stage renal disease; FSP1, fibroblast-specific protein 1; PAS, periodic acid Schiff; rhBMP, recombinant human BMP; STZ, streptozotocin; TGF, transforming growth factor

Diabetic nephropathy is currently the most common cause of end-stage renal disease (ESRD) in the western world. A mouse model for diabetic nephropathy that encompasses the salient features of this disease in the kidney is not available. Here, we report that CD1 mice, in contrast to inbred C57BL/6 and 129Sv strains, develop ESRD associated with prominent tubulointerstitial nephritis and fibrosis within 3 months and die because of diabetic complications by 6–7 months after a single injection of streptozotocin. Histopathologic lesions observed in these mice mimic human diabetic nephropathy, including glomerular hypertrophy, diffuse glomerulosclerosis, tubular atrophy, interstitial fibrosis, and decreased renal excretory function. Next, we tested the therapeutic efficacy of bone morphogenic protein-7 (BMP-7) and inhibitors of advanced glycation end products (AGEs), aminoguanidine and pyridoxamine, to inhibit and regress the progression of renal disease in diabetic CD1 mice. We demonstrate that although aminoguanidine, pyridoxamine, and BMP-7 significantly inhibit glomerular lesions, BMP-7 is most effective in the inhibition of tubular inflammation and tubulointerstitial fibrosis in these mice. Collectively, our results report a new mouse model for diabetic nephropathy with prominent interstitial inflammation and fibrosis and the selective inhibition of diabetic kidney disease by AGE inhibitors and BMP-7.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. M. Mitu, S. Wang, and R. Hirschberg BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1641 - F1648. [Abstract] [Full Text] [PDF]